Drug Profile
VRC-HIVADV014-00-VP
Alternative Names: Ad5HIV-EnvA; HIV adenovector serotype Ad5 vaccine - GenVec/NIAID; rAd5 gag-pol/env A/B/C vaccine; VRC HIV rAd5; VRC HIVADV014 00VPLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator GenVec; National Institute of Allergy and Infectious Diseases; Vaccine Research Center
- Developer GenVec; National Institute of Allergy and Infectious Diseases
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 16 Jun 2017 GenVec has been acquired by Intrexon Corporation
- 01 Jun 2016 NIAID completes a phase Ib trial in HIV infections (Prevention, In volunteers) in USA (NCT01054872)
- 01 Mar 2014 NIAID completes a phase I trial in HIV infections (In volunteers, Prevention) in USA (NCT01386489)